Int J Oral Maxillofac Implants. 2022 Jul-Aug;37(4):722-730. doi: 10.11607/jomi.9413.
The aim of the present retrospective clinical study was to evaluate the outcome of a maxillary sinus lateral window augmentation protocol, which sought to shorten the treatment time.
This protocol entailed sinus augmentation with deproteinized bovine bone minerals (DBBM) and simultaneous implant placement in patients with minimal residual bone height. A total of 89 sinus augmentation procedures were performed in 74 patients, in whom 160 implants were placed between 2005 and 2013. The mean residual bone height was 2.6 ± 0.6 mm. The healing time before loading was 4.18 ± 0.63 months.
In a first evaluation in 2014 the early implant survival rate (EIsR) was 96.8% after a mean period of 5.4 ± 2.2 years. A second evaluation in 2019 after a mean period of 10.4 ± 2.2 years showed a late implant survival rate (LIsR) of 83.1%. The failures after 2014 were all caused by peri-implantitis, which affected 14.6% and 16.8% of patients and implants, respectively. This prevalence of peri-implantitis does not appear to be higher than that usually observed in nonaugmented sites.
This reduction in the duration of treatment compared to the usual duration of 9 to 12 months does not seem to affect the predictability of the technique.
本回顾性临床研究旨在评估一种上颌窦侧壁开窗提升方案的结果,该方案旨在缩短治疗时间。
该方案涉及在骨高度最小残留的患者中使用脱蛋白牛骨矿物质(DBBM)进行鼻窦增强,并同时植入种植体。在 2005 年至 2013 年间,共对 74 名患者的 89 例鼻窦增强手术进行了研究,共植入 160 枚种植体。平均剩余骨高度为 2.6 ± 0.6 毫米。加载前的愈合时间为 4.18 ± 0.63 个月。
在 2014 年的首次评估中,经过 5.4 ± 2.2 年的平均时间后,早期种植体存活率(EIsR)为 96.8%。在 2019 年的第二次评估中,经过 10.4 ± 2.2 年的平均时间后,晚期种植体存活率(LIsR)为 83.1%。2014 年后的失败均由种植体周围炎引起,分别影响了 14.6%和 16.8%的患者和种植体。这种种植体周围炎的患病率似乎并不高于非增强部位通常观察到的患病率。
与通常需要 9 至 12 个月的治疗时间相比,治疗时间的缩短似乎不会影响该技术的可预测性。